LabPas CT Selected By Nucleus Network For Phase I Clinical Trials

Montpelier, Vermont, April 30, 2007 — Nucleus Network, an internationally renowned clinical research center located in Melbourne, Australia, has selected LabPas CT to fully automate their Phase I clinical trials.

According to Andrew Giddy, CEO of Nucleus Network, “LabPas CT’s comprehensive automation of the Phase I laboratory, clinic floor, recruiting, and sample storage enhances our commitment to provide sponsors with operational and service excellence by increasing compliance and speeding trials. It also helps position our new 24-bed, state-of-the-art Phase I facility as the preeminent clinical research center in Australia.”

John Rosenblum, CEO of Green Mountain Logic, the developer of LabPas CT, added, “Nucleus Network is a very important partner for us. They are held in high regard by pharmaceutical and biotechnology sponsors throughout the world, and have very generously agreed to act as a LabPas CT demonstration site for Australia and Asia.”

Nucleus Network is the sixth highly regarded clinical research organization in the past year – and the second international clinic in the last month – to select LabPas CT. Others include CEDRA, Acclaim Pharma Research, Advanced Biomedical Research, Arkansas Clinical Research and a major Midwest health care facility. LabPas CT, the leading software solution for Phase I clinical trials, improves margins, decreases liability and increases clinical capabilities. LabPas CT is unique in its intuitive use and adaptability to individual study protocols.

Nucleus Network is the gateway for access to Australian medical and research communities for global product development and clinical trials. Nucleus brings together leaders in health and life sciences innovation and clinical operation capabilities. The network includes more than 85 years of cumulative experience and the practical conduct of over 350 clinical trials.
<!–[if !supportLineBreakNewLine]–>
<!–[endif]–>

Nucleus Network conducts clinical research nationally and internationally within Australia, Europe, Asia and the United States. They provide a broad range of expertise on clinical research and product development to the global pharmaceutical, biotechnology and medical device industries through:

  • A dedicated, self-contained, state-of-the-art 24-bed clinical trial unit with additional access to a full teaching hospital environment.
  • The conduct of clinical trials (Phases I-IV) with a specialized focus on early phase studies.
  • Clinical research consulting, focusing on entry to clinical development.
  • Network partners, including all services, infrastructure and knowledge along the product development chain.

To learn more about Nucleus Network visit www.nucleusnetwork.com.au.

To learn more about LabPas CT visit www.labpas.com.